O	0	5	First
O	6	9	and
O	10	20	subsequent
O	21	26	cycle
O	27	30	use
O	31	33	of
B-intervention	34	47	pegfilgrastim
O	48	56	prevents
B-condition	57	64	febrile
I-condition	65	76	neutropenia
O	77	79	in
O	80	88	patients
O	89	93	with
O	94	100	breast
O	101	107	cancer
O	107	108	:
O	109	110	a
O	111	122	multicenter
O	122	123	,
O	124	130	double
O	130	131	-
O	131	136	blind
O	136	137	,
O	138	145	placebo
O	145	146	-
O	146	156	controlled
O	157	162	phase
O	163	166	III
O	167	172	study
O	172	173	.

O	174	176	We
O	177	186	evaluated
O	187	190	the
O	191	199	efficacy
O	200	202	of
O	203	216	pegfilgrastim
O	217	219	to
O	220	226	reduce
O	227	230	the
O	231	240	incidence
O	241	243	of
O	244	251	febrile
O	252	263	neutropenia
O	264	274	associated
O	275	279	with
O	280	289	docetaxel
O	290	292	in
O	293	299	breast
O	300	306	cancer
O	307	315	patients
O	315	316	.

O	317	325	Patients
O	326	330	were
O	331	339	randomly
O	340	348	assigned
O	349	351	to
O	352	358	either
B-control	359	366	placebo
O	367	369	or
O	370	383	pegfilgrastim
O	384	385	6
O	386	388	mg
O	389	403	subcutaneously
O	404	406	on
O	407	410	day
O	411	412	2
O	413	415	of
O	416	420	each
O	421	423	21
O	423	424	-
O	424	427	day
O	428	440	chemotherapy
O	441	446	cycle
O	447	449	of
O	450	453	100
O	454	456	mg
O	456	457	/
O	457	458	m
O	458	459	(
O	459	460	2
O	460	461	)
O	462	471	docetaxel
O	471	472	.

O	473	476	The
O	477	484	primary
O	485	488	end
O	489	494	point
O	495	498	was
O	499	502	the
B-outcome-Measure	503	513	percentage
I-outcome-Measure	514	516	of
I-outcome-Measure	517	525	patients
I-outcome-Measure	526	536	developing
I-outcome-Measure	537	544	febrile
I-outcome-Measure	545	556	neutropenia
O	557	558	(
O	558	565	defined
O	566	568	as
O	569	573	body
O	574	585	temperature
O	586	587	>
O	587	588	/
O	588	589	=
O	590	592	38
O	592	593	.
O	593	594	2
O	595	602	degrees
O	603	604	C
O	605	608	and
O	609	619	neutrophil
O	620	625	count
O	626	627	<
O	628	629	0
O	629	630	.
O	630	631	5
O	632	633	x
O	634	636	10
O	636	637	(
O	637	638	9
O	638	639	)
O	639	640	/
O	640	641	L
O	642	644	on
O	645	648	the
O	649	653	same
O	654	657	day
O	658	660	of
O	661	664	the
O	665	670	fever
O	671	673	or
O	674	677	the
O	678	681	day
O	682	687	after
O	687	688	)
O	688	689	.

O	690	699	Secondary
O	700	703	end
O	704	710	points
O	711	715	were
B-outcome-Measure	716	725	incidence
I-outcome-Measure	726	728	of
I-outcome-Measure	729	745	hospitalizations
I-outcome-Measure	746	756	associated
I-outcome-Measure	757	761	with
I-outcome-Measure	762	763	a
I-outcome-Measure	764	773	diagnosis
I-outcome-Measure	774	776	of
I-outcome-Measure	777	784	febrile
I-outcome-Measure	785	796	neutropenia
O	796	797	,
B-outcome-Measure	798	809	intravenous
I-outcome-Measure	810	811	(
I-outcome-Measure	811	813	IV
I-outcome-Measure	813	814	)
I-outcome-Measure	815	819	anti
I-outcome-Measure	819	820	-
I-outcome-Measure	820	830	infectives
I-outcome-Measure	831	839	required
I-outcome-Measure	840	843	for
I-outcome-Measure	844	851	febrile
I-outcome-Measure	852	863	neutropenia
O	863	864	,
O	865	868	and
O	869	872	the
B-outcome-Measure	873	880	ability
I-outcome-Measure	881	883	to
I-outcome-Measure	884	892	maintain
I-outcome-Measure	893	900	planned
I-outcome-Measure	901	913	chemotherapy
I-outcome-Measure	914	918	dose
I-outcome-Measure	919	921	on
I-outcome-Measure	922	926	time
O	926	927	.

O	928	936	Patients
O	937	941	with
O	942	949	febrile
O	950	961	neutropenia
O	962	966	were
O	967	976	converted
O	977	979	to
O	980	984	open
O	984	985	-
O	985	990	label
O	991	1004	pegfilgrastim
O	1005	1007	in
O	1008	1018	subsequent
O	1019	1025	cycles
O	1025	1026	.

B-total-participants	1027	1031	Nine
I-total-participants	1032	1039	hundred
I-total-participants	1040	1046	twenty
I-total-participants	1046	1047	-
I-total-participants	1047	1052	eight
O	1053	1061	patients
O	1062	1070	received
O	1071	1078	placebo
O	1079	1080	(
O	1080	1081	n
O	1082	1083	=
B-control-participants	1084	1087	465
O	1087	1088	)
O	1089	1091	or
O	1092	1105	pegfilgrastim
O	1106	1107	(
O	1107	1108	n
O	1109	1110	=
B-intervention-participants	1111	1114	463
O	1114	1115	)
O	1115	1116	.

O	1117	1125	Patients
O	1126	1135	receiving
O	1136	1149	pegfilgrastim
O	1149	1150	,
O	1151	1159	compared
O	1160	1164	with
O	1165	1173	patients
O	1174	1183	receiving
O	1184	1191	placebo
O	1191	1192	,
O	1193	1196	had
O	1197	1198	a
O	1199	1204	lower
B-outcome	1205	1214	incidence
I-outcome	1215	1217	of
I-outcome	1218	1225	febrile
I-outcome	1226	1237	neutropenia
O	1238	1239	(
B-iv-bin-percent	1239	1240	1
I-iv-bin-percent	1240	1241	%
O	1242	1243	v
B-cv-bin-percent	1244	1246	17
I-cv-bin-percent	1246	1247	%
O	1247	1248	,
O	1249	1261	respectively
O	1261	1262	;
O	1263	1264	P
O	1265	1266	<
O	1267	1268	.
O	1268	1271	001
O	1271	1272	)
O	1272	1273	,
B-outcome	1274	1281	febrile
I-outcome	1282	1293	neutropenia
I-outcome	1293	1294	-
I-outcome	1294	1301	related
I-outcome	1302	1317	hospitalization
O	1318	1319	(
B-iv-bin-percent	1319	1320	1
I-iv-bin-percent	1320	1321	%
O	1322	1323	v
B-cv-bin-percent	1324	1326	14
I-cv-bin-percent	1326	1327	%
O	1327	1328	,
O	1329	1341	respectively
O	1341	1342	;
O	1343	1344	P
O	1345	1346	<
O	1347	1348	.
O	1348	1351	001
O	1351	1352	)
O	1352	1353	,
O	1354	1357	and
B-outcome	1358	1361	use
I-outcome	1362	1364	of
I-outcome	1365	1367	IV
I-outcome	1368	1372	anti
I-outcome	1372	1373	-
I-outcome	1373	1383	infectives
O	1384	1385	(
B-iv-bin-percent	1385	1386	2
I-iv-bin-percent	1386	1387	%
O	1388	1389	v
B-cv-bin-percent	1390	1392	10
I-cv-bin-percent	1392	1393	%
O	1393	1394	,
O	1395	1407	respectively
O	1407	1408	;
O	1409	1410	P
O	1411	1412	<
O	1413	1414	.
O	1414	1417	001
O	1417	1418	)
O	1418	1419	.

O	1420	1423	The
B-outcome	1424	1434	percentage
I-outcome	1435	1437	of
I-outcome	1438	1446	patients
I-outcome	1447	1456	receiving
I-outcome	1457	1460	the
I-outcome	1461	1468	planned
I-outcome	1469	1473	dose
I-outcome	1474	1476	on
I-outcome	1477	1481	time
O	1482	1485	was
O	1486	1493	similar
O	1494	1501	between
O	1502	1510	patients
O	1511	1520	receiving
O	1521	1534	pegfilgrastim
O	1535	1538	and
O	1539	1547	patients
O	1548	1551	who
O	1552	1561	initially
O	1562	1570	received
O	1571	1578	placebo
O	1579	1580	(
B-iv-bin-percent	1580	1582	80
I-iv-bin-percent	1582	1583	%
O	1584	1587	and
B-cv-bin-percent	1588	1590	78
I-cv-bin-percent	1590	1591	%
O	1591	1592	,
O	1593	1605	respectively
O	1605	1606	)
O	1606	1607	,
O	1608	1610	as
O	1611	1616	would
O	1617	1619	be
O	1620	1628	expected
O	1629	1631	of
O	1632	1635	the
O	1636	1641	study
O	1642	1648	design
O	1648	1649	.

O	1650	1663	Pegfilgrastim
O	1664	1667	was
O	1668	1677	generally
B-outcome	1678	1682	well
I-outcome	1683	1692	tolerated
I-outcome	1693	1696	and
I-outcome	1697	1701	safe
O	1701	1702	,
O	1703	1706	and
O	1707	1710	the
B-outcome	1711	1718	adverse
I-outcome	1719	1725	events
O	1726	1734	reported
O	1735	1739	were
O	1740	1747	typical
O	1748	1750	of
O	1751	1755	this
O	1756	1763	patient
O	1764	1774	population
O	1774	1775	.

O	1776	1781	First
O	1782	1785	and
O	1786	1796	subsequent
O	1797	1802	cycle
O	1803	1806	use
O	1807	1809	of
O	1810	1823	pegfilgrastim
O	1824	1828	with
O	1829	1830	a
O	1831	1841	moderately
O	1842	1858	myelosuppressive
O	1859	1871	chemotherapy
O	1872	1879	regimen
O	1880	1888	markedly
O	1889	1896	reduced
O	1897	1904	febrile
O	1905	1916	neutropenia
O	1916	1917	,
O	1918	1925	febrile
O	1926	1937	neutropenia
O	1937	1938	-
O	1938	1945	related
O	1946	1962	hospitalizations
O	1962	1963	,
O	1964	1967	and
O	1968	1970	IV
O	1971	1975	anti
O	1975	1976	-
O	1976	1985	infective
O	1986	1989	use
O	1989	1990	.
